Literature DB >> 3100057

Proliferation of human peripheral blood lymphocytes induced by recombinant human interleukin 2: contribution of large granular lymphocytes and T lymphocytes.

J E Talmadge, R H Wiltrout, D F Counts, R B Herberman, T McDonald, J R Ortaldo.   

Abstract

Recombinant human interleukin 2 (rH IL-2) in the presence or absence of additional stimuli, was found to be able to induce and support the proliferation of human peripheral blood lymphocytes (PBLs). These proliferative effects were observed at low doses (less than or equal to 10 U/ml) of interleukin 2 (IL-2) only when additional signals (antigen, mitogen) were provided. However, higher doses (greater than or equal to 100 U/ml) of rH IL-2 significantly stimulated the proliferation of PBL even in the absence of exogenous lectin, antigen, or allogeneic serum. The subpopulation of lymphocytes most responsive to these higher doses of rH IL-2 was the large granular lymphocyte (LGL), the morphologic homologue of natural killer activity. After the separation of human PBLs on discontinuous Percoll gradients, cells from fraction 2 (greater than 90% LGLs) responded in a dose-dependent manner to rH IL-2 alone, whereas cells from fraction 6 (greater than 90% T cells) were only slightly responsive to rH IL-2 alone. A portion of the proliferation of cells from fraction 2 was dependent on the expression of the TAC receptor, because the prior removal of TAC-positive cells significantly reduced IL-2-induced lymphocyte proliferation. These results demonstrate that human LGL that have not been exogenously stimulated can proliferate in direct response to IL-2, and suggest that LGL are the major cellular phenotype in the proliferative response that has been observed clinically.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3100057     DOI: 10.1016/0008-8749(86)90420-x

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  11 in total

1.  Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells.

Authors:  J H Kehrl; M Dukovich; G Whalen; P Katz; A S Fauci; W C Greene
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

Review 2.  Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations.

Authors:  R E Merchant; M D Ellison; H F Young
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

3.  Recombinant human interleukin-2-induced mitogenic proliferation of in vitro unstimulated bovine intestinal lymphocytes.

Authors:  A M Nagi; L A Babiuk
Journal:  Can J Vet Res       Date:  1989-01       Impact factor: 1.310

4.  Interleukin 2 receptor expression by human blood lymphocytes after vaccination with pneumococcal polysaccharides.

Authors:  N Tvede; C Heilmann; L D Christensen
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

5.  Lymphocytes expressing type 3 complement receptors proliferate in response to interleukin 2 and are the precursors of lymphokine-activated killer cells.

Authors:  J D Gray; D A Horwitz
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

6.  HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients.

Authors:  R A Janssen; J Buter; E Straatsma; A A Heijn; D T Sleijfer; E G de Vries; N H Mulder; T H The; L de Leij
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

7.  Interleukin-2-induced lymphoproliferative responses.

Authors:  A Winkelstein; L D Weaver; N Salva; L L Machen
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

8.  A strategy for evaluating lymphokine activation and novel monoclonal antibodies in antibody-dependent cell-mediated cytotoxicity and effector cell retargeting assays.

Authors:  R P Junghans
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

9.  Studies of lymphokine-activated killer (LAK) cells. I. Evidence using novel monoclonal antibodies that most human LAK precursor cells share a common surface marker.

Authors:  D G Morris; H F Pross
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

10.  Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells.

Authors:  N L Vujanovic; R B Herberman; A A Maghazachi; J C Hiserodt
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.